Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.
Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, Zach J, Novak M, Marinov I, Soverini S, Faber E, Machova Polakova K. Polivkova V, et al. Among authors: cerna o. PLoS One. 2016 May 23;11(5):e0155959. doi: 10.1371/journal.pone.0155959. eCollection 2016. PLoS One. 2016. PMID: 27214026 Free PMC article.
Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.
Schwarz J, Ovesná P, Černá O, Kissová J, Maaloufová Soukupová J, Brychtová Y, Doubek M, Červinek L, Cmunt E, Dulíček P, Campr V, Křen L, Penka M; CZEMP-Czech Group for Ph- Myeloproliferative Disorders. Schwarz J, et al. Among authors: cerna o. Eur J Haematol. 2016 Jan;96(1):98-106. doi: 10.1111/ejh.12554. Epub 2015 Apr 21. Eur J Haematol. 2016. PMID: 25807961
[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine].
Penka M, Schwarz J, Pavlík T, Pytiĺk R, Doubek M, Dulícek P, Kissová J, Hlusi A, Schutzová M, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Dusek L. Penka M, et al. Among authors: cerna o. Vnitr Lek. 2008 Jul-Aug;54(7-8):775-82. Vnitr Lek. 2008. PMID: 18780577 Czech.
[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M, Doubek M, Schwarz J, Pytlík R, Dulícek P, Kissová J, Hlusí A, Vozobulová V, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Schutzová M, Hadacová I, Hochová I, Voglová J, Siroký O, Belada D, Lhot'anová T, Bubeník B, Vránová M, Micaníková M, Dusek L. Penka M, et al. Among authors: cerna o. Vnitr Lek. 2006 May;52(5):498-503. Vnitr Lek. 2006. PMID: 16771099 Czech.
[Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
Penka M, Schwarz J, Pavlík T, Pytlík R, Doubek M, Dulícek P, Pospísilová D, Kissová J, Hlusí A, Schützová M, Cerná O, Brychtová Y, Szotkowski T, Volková Z, Seghetová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Lhotanová T, Bubeník B, Zapletal O, Vránová M, Micaníková M, Dusek L. Penka M, et al. Among authors: cerna o. Vnitr Lek. 2007 Jun;53(6):653-61. Vnitr Lek. 2007. PMID: 17702125 Czech.
[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
Penka M, Schwarz J, Pavlík T, Indrák K, Doubek M, Dulícek P, Pospísilová D, Kissová J, Jonásová A, Jelínková P, Hlusí A, Schutzová M, Cerná O, Brychtová Y, Nováková L, Korístek Z, Segethová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Walterová L, Bodzásová C, Dusek L. Penka M, et al. Among authors: cerna o. Vnitr Lek. 2009 Nov;55(11):I-XII. Vnitr Lek. 2009. PMID: 20017445 Clinical Trial. Czech.
[Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ].
Penka M, Schwarz J, Campr V, Pospíšilová D, Křen L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulíček P, Jonášová A, Kissová J, Kořístek Z, Schützová M, Vonke I, Walterová L; Czech Working Group of the Czech Hematologic Society CLS JEP. Penka M, et al. Among authors: cerna o. Vnitr Lek. 2012 Feb;58(2):163-8. Vnitr Lek. 2012. PMID: 22463098 Czech. No abstract available.
44 results